Dry Eye Clinical Trial
Official title:
Lipiflow vs iLux Patient Acceptance and Comfort Study
This study was designed to compare patient acceptance, comfort, and preference between two meibomian gland clearing devices (Lipiflow vs, iLux). Primary Objective was to compare patient comfort as assessed by Likert-style scale questionnaire following each bilateral procedure. Secondary Objective was to compare overall experience and treatment preference as assessed by Likert-style questionnaire following each bilateral procedure. Both devices are exempt from IDE regulations [21 CFR 812.2(c)].
Introduction Meibomian gland disease (MGD) is increasingly recognized as a primary cause or
contributor to tear instability and dry eye disease. Effective management of this disorder
often requires meibomian gland expression and clearance. A variety of devices which apply
pressure, heat or a combination of both to the glands have been used.
Two such devices that apply heat and pressure simultaneously are commercially available.
LipiFlow (JNJ Vision Care) is an automated computer-controlled device that uses vectored
thermal (hydraulic) pulsation applied by an activator device placed on the eye between the
globe and the eyelids to achieve gland clearance. The iLux System (Alcon) is an operator
controlled assisted manual device which applies heat generated by infrared LEDs and
expression through cam driven mechanical pressure applied to the lids.
Device Descriptions LipiFlow Thermal Pulsation System
The Lipiflow Thermal Pulsation System is a commercially available device used in the
treatment of MGD. It is cleared to be marketed by the United States Food and Drug
Administration. The LipiFlow Thermal Pulsation System is intended for the application of
localized heat and pressure therapy in adult patients with chronic cystic conditions of the
eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye or
lipid deficiency dry eye.
The LipiFlow Console provides the user interface and control elements of the system,
including all software, algorithms and control elements. The Activator, a single-use sterile
device, delivers automated therapeutic energies to each meibomian gland. Its contoured design
vaults the cornea and protects the eye allowing a maximum therapeutic temperature of 43
degrees Celsius to reach glands from the inner eyelid, without damaging the eyelid or
delicate structures of the globe. Insulation protects the cornea from exceeding a safe 39.5
degrees Celsius, while a pressure feedback loop sends pulsed sequences to expel blockages.
Force equalization protects the globe from pressure transmission by focusing energy only on
the eyelid. Delivered through the LipiFlow Activator, Vectored Thermal Pulse™ (VTP)
technology applies a combination of heat and pressure to the inner eyelid to safely remove
gland obstructions and stagnant gland content. Vectored heat and adaptive force equalization
target the pulse, heat, and pressure on the meibomian glands to maximize effectiveness.
Therapeutic motion provides proximal-to-distal peristalsis to clear gland contents.
iLux System
The iLux™ System is a medical device commercially available for use by Eye Care Professionals
(ECP) to apply localized heat and pressure therapy to a patient's eyelids. It is cleared to
be marketed by the United States Food and Drug Administration. The system consists of a
handheld instrument coupled to a single-use, sterile disposable component that is positioned
to bridge the eyelid. The iLux device allows an ECP to view the eyelid margin through a
magnifier, then warm the eyelid tissue to a range of 40 to 42˚C, and then apply force-limited
compression to the eyelid in order to express melted meibum from obstructed glands. The iLux
System is indicated for the application of localized heat and pressure therapy in adult
patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction
(MGD), also known as evaporative dry eye.
The iLux Instrument is a handheld, electronic instrument used together with the iLux
disposable to apply heating and pressure to the eyelid. The Instrument includes electronic
circuits that read sensors in the Inner and Outer Eyelid Pads to measure temperatures
representative of inner and outer eyelid temperature, respectively. Warming is accomplished
using light energy emitted from LEDs in the Instrument. The LEDs are located behind a clear
window on the open end of the Shroud. Two wavelengths of light are used: lime-green (568 nm)
and near-infrared (850 nm). A mechanism in the Instrument allows the operator to apply
pressure to the eyelid by controlling the movement of the Outer Pad using finger pressure
applied to the Compression Control button. The force applied to the Compression Control is
measured by a sensor in this mechanism. A graphic Screen displays information for operating
the Instrument during a treatment.
Study Purpose / Objectives This study is designed to compare patient acceptance, comfort, and
preference between two meibomian gland clearing devices. Both devices are exempt from IDE
regulations [21 CFR 812.2(c)]. Primary Objective is to compare patient comfort as assessed by
Likert-style scale questionnaire following each bilateral procedure. Secondary Objective is
to compare overall experience and treatment preference as assessed by Likert-style
questionnaire following each bilateral procedure.
Background "Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland
Dysfunction" listed on ClincalTrials.gov looked at a 4-week efficacy comparison between the
two treatment devices. Pain and discomfort data were collected regarding the two procedures
but was not analyzed for significance due to no pre-trial hypothesis. The raw data shows
lower pain and discomfort scores immediately following the procedure for the Lipiflow as
compared to iLux with similar pre-treatment and one-day post post-treatment scores (Thornhill
2019). There is currently no published research on the patient acceptance, comfort, and
preference comparing any meibomian gland emptying devices.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |